Sonnet biotherapeutics provides fiscal year 2024 second quarter and year-to-date business and earnings update

Published phase 1 data of son-1010 in frontiers in immunology demonstrating the safety and tolerability of the f h ab-derived interleukin 12 in healthy volunteers announced early safety data from the company's phase 1b/2a clinical trial of son-080 in patients with chemotherapy-induced peripheral neuropathy (cipn) received $4.3 million in net proceeds from the sale of net operating losses through the new jersey technology business tax certificate transfer program presented preclinical data and information on the clinical trial design from the study of son-080 in cipn in a poster session at the american association for cancer research (aacr) annual meeting princeton, nj / accesswire / may 14, 2024 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months and six months ended march 31, 2024 and provided a business update. "we are very excited about the progress we made during the first calendar quarter of this year with the son-1010 and son-080 programs, where the foundations for the compounds' safety profiles were further strengthened.
SONN Ratings Summary
SONN Quant Ranking